Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TLX300-CDx
- Development stage
- Phase 1
- Lead developer
- Telix Pharmaceuticals
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
TLX300-CDx is a radiolabeled monoclonal antibody diagnostic agent developed for use in positron emission tomography (PET) imaging. It consists of olaratumab—a human monoclonal antibody that targets platelet-derived growth factor receptor alpha (PDGFRα)—conjugated to the radioisotope zirconium-89 (^89Zr). PDGFRα is frequently overexpressed in soft tissue sarcoma (STS), making it a rational target for both diagnostic and potential therapeutic applications. The primary mechanism involves binding to PDGFRα-expressing tumor cells and enabling PET-based visualization of tumors for patient selection and dosimetry prior to targeted radionuclide therapy. The agent is being evaluated in first-in-human Phase 1 trials as part of a theranostic approach to optimize subsequent therapeutic strategies for advanced or metastatic STS[1][5][8].
- Brand names
- TLX300-CDxTLX-300-CDxTLX 300-CDx
- Other names
- 89Zr-olaratumabradionuclide olaratumab conjugate
02
Targets
PDGFRA (Platelet-derived growth factor receptor alpha)
Beyond the preview
Go deeper on TLX300-CDx.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TLX300-CDx.